Organigram Global: Sanity Group integrated Into Global Corporate Structure

Organigram Global and Sanity Group Announce Successful Closing of Acquisition

Evaluation Report on Second Anniversary of German Cannabis Act: Sanity Group Calls for Evidence-Based Regulation

Sanity Group and Curaleaf Laboratories Announce Partnership to Advance Medical Cannabis Innovation in the UK

Sanity Group Becomes Part of Canadian Cannabis Market Leader Organigram Global to Drive International Growth

Two Years of Legal Cannabis from Specialized Retail Stores: Swiss Pilot Project Shows Positive Effects on Health Protection, Consumer Competence, and Combating the Illicit Market

Research application initially rejected: Scientific pilot project on recreational cannabis in Frankfurt and Hanover denied regulatory approval

Coalition Agreement Presented: Sanity Group Welcomes Planned Evaluation of Cannabis Law and Calls for Scientific Pilot Projects

Cannabis Dispensaries in the German Capital: Sanity Group Plans Scientific Pilot Projects with Two Berlin Districts

Sanity Group Secures Additional Growth Capital Amounting to a Total of 17 Million Euros

Federal Council: Cannabis Legalization to Take Effect on April 1st

First legal cannabis dispensaries in Europe: Sanity Group and ISGF get green light for a cannabis study in Swiss canton Basel-Landschaft

Europe’s first legal cannabis specialist store has opened: “Grashaus Projects” in Switzerland officially launched

Cannabis legalization in Germany: Sanity Group’s assessment of the official draft bill on Pillar 1

Exclusive partnerships: Sanity Group launches international distribution of its medical cannabis brands Vayamed and avaay Medical with exclusive partners in Europe

Cannabis legalization in Germany – Statement on the revised cornerstone paper

Endosane Pharmaceuticals agrees to Licence Agreement with PreveCeutical Medical thereby Securing Exclusive Rights to Innovative Technology

Sanity Group welcomes aspects of the official document outlining the key points on cannabis legalization, but sees room for improvement

German Cannabis company Sanity Group announces $37.6 Million Series B funding round

Portugal, South Africa and Canada: Sanity Group strengthens and diversifies its global partner network

Sanity Group has expanded its management team

Vayamed Cannakits®: Innovative cannabis formulation kits enable new forms of application for an expanded therapy spectrum – experienced therapists sought for clinical support survey

Sanity Group at the hemp fair Mary Jane and ICBC Berlin 2022

Vayamed and telemedicine pioneer Telaleaf launch exclusive partnership

Endosane and UCI investigate the efficacy of new compounds for the treatment of PTSD

Sanity Group appreciates the controlled dispensing of cannabis as stated in the coalition agreement

Sanity Group Closes $3.5M Follow-On Investment by Casa Verde Capital

Endosane: International scientists team up with Sanity Group in a joint-venture aiming to develop a new generation of “game changing” psychiatric drugs with significantly reduced side effect profile​

Liqui-Patch: Sanity Group and epinamics launch strategic partnership for transdermal cannabinoid applications